Stem cell grafts - Miltenyi Biotech

Drug Profile

Stem cell grafts - Miltenyi Biotech

Alternative Names: TCRabCD19PBSC

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Miltenyi Biotec GmbH
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer; Haematological disorders; Immunodeficiency disorders; Metabolic disorders

Most Recent Events

  • 03 Dec 2016 Adverse events data from a phase I/II trial in Cancer, Haematological disorders, Immunodeficiency disorders and Metabolic disorders presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top